The choroidal neovascularization market is witnessing steady momentum as ophthalmology continues to shift from chronic, injection-heavy management toward durable, mechanism-driven therapies. This condition, marked by abnormal blood vessel growth beneath the retina, remains a leading contributor to central vision loss worldwide, particularly among aging populations and individuals with high myopia. With established anti-VEGF agents holding the current standard of care and a wave of gene therapies advancing through late-stage trials, the treatment landscape for this disease is set for meaningful transformation between 2025 and 2034.
Understanding Choroidal Disease
The choroidal layer sits beneath the retina and, when disrupted, can give rise to abnormal vessels that leak fluid or blood, distorting vision. This process is most often triggered by neovascular (wet) age-related macular degeneration, pathological myopia, or underlying inflammatory conditions. In the US, myopic forms of the disease affect a small but clinically significant share of the population, while in Germany, pathological myopia impacts roughly 1–3% of people, with a notable proportion going on to develop vascular complications. Elevated levels of vascular endothelial growth factor, driven by hypoxia and oxidative stress, sit at the center of this process, prompting abnormal angiogenesis and vessel permeability. Diagnosis typically relies on optical coherence tomography and fluorescein angiography to detect fluid accumulation and confirm active disease, helping physicians distinguish it from other retinal disorders and plan an appropriate course of treatment.
The Choroidal Neovascular Membrane and Disease Burden
At the histological level, the hallmark of this disorder is the formation of a choroidal neovascular membrane — a network of fragile new vessels that penetrate Bruch’s membrane and extend into the retinal pigment epithelium and neurosensory retina. This membrane is responsible for the bleeding, scarring, and fluid leakage that ultimately threaten central vision if left untreated. Epidemiological data underscore the scale of this burden: nearly 1.5 million people in the US live with wet or late-stage age-related macular degeneration, while Germany reports around 3.27 million affected individuals. France shows a disease prevalence of roughly 1.06%, rising sharply with age and skewing toward female patients, and Japan’s figures point to a distinct pattern in which high myopia plays an outsized role in driving new cases. Together, these regional variations highlight why early detection and consistent monitoring remain central priorities for clinicians and health systems alike.
Anti-VEGF MOA: Current Standard of Care
Modern management is built around the anti VEGF MOA, which works by directly suppressing the signaling pathways responsible for abnormal vessel growth and leakage. VABYSMO (faricimab-svoa) from Genentech introduced a first-in-class bispecific approach, targeting both angiopoietin-2 and VEGF-A to stabilize retinal vasculature with extended dosing intervals. BEOVU (brolucizumab-dbll) from Novartis followed a related path, using a single-chain antibody fragment engineered for deeper tissue penetration and sustained disease control. Both therapies have reshaped clinical practice by improving visual acuity outcomes while reducing the frequency of intravitreal injections, though variable patient response and treatment burden continue to drive interest in longer-acting alternatives, including laser photocoagulation and photodynamic therapy for select cases.
Retinal Neovascularization Market Landscape
Looking ahead, the broader retinal neovascularization market is being reshaped by a new generation of one-time gene therapies designed to reduce or eliminate repeated injections altogether. Surabgene lomparvovec (ABBV-RGX-314), developed by AbbVie and REGENXBIO, uses an AAV8 vector to enable continuous intraocular anti-VEGF expression, with pivotal trial data expected in 2026. NG101 from Neuracle Genetics recently secured FDA Fast Track Designation and completed early-cohort dosing, while Ixoberogene soroparvovec from Adverum Biotechnologies has advanced into a pivotal Phase III program, with full enrollment targeted for late 2025 and a data readout anticipated in early 2027. Collectively, these candidates signal a shift toward personalized, sustained-release solutions capable of easing the clinical burden associated with lifelong intravitreal therapy.
Outlook
Across the seven major markets — the US, EU4, UK, and Japan — rising disease prevalence, improved screening infrastructure, and the anticipated entry of gene therapies are expected to drive continued expansion through 2034. As diagnostic tools improve and treatment options diversify, stakeholders across the industry are well positioned to capture emerging opportunities while addressing the persistent unmet needs of patients facing this vision-threatening condition.
Latest Reports Offered by Delveinsight
uk healthcare report, varicose vein market, antibody drug conjugate market, bone grafts and substitutes market, chemotherapy induced anemia market, hypoventilation market, paget’s disease market, stem cell market, vascular grafts market, celiac disease market, dental implants and prosthesis market, diabetic retinopathy market, dilators market, eisenmenger complex market, endoscopic ultrasound market, erectile dysfunction market, exophthalmos market, mrna based vaccines and therapeutics market, spinal cord stimulators market, von willebrand disease market, aesthetic implants market, biliary tumor market, catheter stabilization devices market, compartment syndrome market, donohue syndrome market, fibrocystic breast condition market, hearing implants market
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk